

Cell Therapy and T-Cell Receptor Technologies Available for Licensing and co-development

<http://techtransfer.cancer.gov/availabletechnologies>

Lead Inventor	Title	Therapeutic Area	Reference #
James Kochenderfer	Chimeric Antigen Receptors Targeting the Gamma Delta ($\gamma\delta$) T-Cell Receptor	Oncology Immunology	TAB-5073 E-214-2024-0
Scott Norberg	Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s)	Infectious Disease Immunology	TAB-5072 E-143-2024-0
Paul Love	Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1	Oncology Immunology	TAB-5065 E-004-2024-0
Jay Berzofsky	Compositions and Methods for Producing Dendric Cell-based Vaccines with Enhanced Efficacy	Oncology Immunology	TAB-5066 E-231-2023-0
Brad St. Croix	Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors	Oncology Immunology	TAB-5022 E-125-2023-0
Zhiya Yu	T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy	Cancers expressing the BRAF V600E mutation	TAB-4197 E-213-2022-0
Sri Krishna	T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy	Cancers expressing CDKN2A mutations	TAB-4389 E-206-2022-0
Sri Krishna	Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer	Combination immunotherapy	TAB-4257 E-046-2022-0
Ira Pastan	Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent	Cancers expressing mesothelin	TAB-4322 E-033-2022-0
Mitchell Ho	Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge and Transmembrane Domains for Treating Neuroblastoma	Cancers expressing GPC2	TAB-4321 E-025-2022-0

Cell Therapy and T-Cell Receptor Technologies Available for Licensing and co-development

<http://techtransfer.cancer.gov/availabletechnologies>

Mitchell Ho	IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer	Liver cancer treatment	TAB-4043 E-205-2021-0
Joost Oppenheim	Immunotherapy Combination Treatment Containing both TLR4 and TLR2/6 Agonists, a Checkpoint Inhibitor, and a STING agonist	Combination immunotherapy	TAB-4040 E-181-2021-0
Mitchell Ho	Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors	Targeting domain in CARs, ADCs, RITs	TAB-3949 E-118-2021-0
Mitchell Ho	Combination of recombinant IL-7 with Chimeric Antigen Receptor (CAR) T Cells Targeting Glypican-3 (GPC3) for the Treatment of Hepatocellular Carcinoma (HCC)	Hepatocellular carcinoma	TAB-4196 E-108-2021-0
James Kochenderfer	Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20	Cancers expressing CD19 and CD20	TAB-4140 E-065-2021-0
Paul Love	Enhanced Antigen Reactivity of Immune Cells Expressing a mMutant Non-Signaling CD3 Zeta Chain	Immunotherapy	TAB-4319 E-010-2021-0
Kazusa Ishii	T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias	Lymphomas and Leukemias	TAB-3990 E-152-2020-0
Mitchell Ho	IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors	Cancers expressing GPC1	TAB-4136 E-107-2020-0
Rami Yoseph	Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients	Method to identify neoantigen-specific TCRs	TAB-4145 E-102-2020-0

Cell Therapy and T-Cell Receptor Technologies Available for Licensing and co-development

<http://techtransfer.cancer.gov/availabletechnologies>

Steven Rosenberg	Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)	Method to identify neoantigen-specific TCRs	TAB-4326 E-061-2020-0
Leonard Warren	Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy	Immunotherapy	TAB-4352 E-126-2019-0
James Kochenderfer	Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20	Cancers expressing CD19 and CD20	TAB-4082 E-205-2018-0
James Kochenderfer	Anti-SLAMF7 Chimeric Antigen Receptors	Multiple myeloma	TAB-3991 E-158-2018-0
Lisa Pasquet	3-o-sulfo-galactosylceramide Analogs as Activators of Type II Natural Killer T (NKT) Cells to Reduce Cancer Metastasis to the Lung	Cancer metastasis	TAB-4135 E-100-2018-0
Mitchel Ho	New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies	Method to increase efficiency of CAR T therapy	TAB-4113 E-016-2018-0
Nicholas Restifo	Methods of Producing T-cell Populations Using P38 MAPK Inhibitors	Method to increase efficiency of CAR T therapy	TAB-4243 E-002-2018-0
Drew Deniger	T Cell Receptors Targeting p53 Mutations for Cancer Immunotherapy and Adoptive Cell Therapy	Cancers expressing mutant p53	TAB-4297 E-237-2017-0 E-237-2017-1 E-237-2017-2
Tim Greten	Bile Acids and Other Agents that Modulate the Gut Microbiome for the Treatment of Liver Cancer	Liver cancer	TAB-3909 E-229-2017-0
James Kochenderfer	Fully human Heavy-chain-only Anti-B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptors (CARs)	Blood cancers	TAB-4230 E-183-2017-0

Cell Therapy and T-Cell Receptor Technologies Available for Licensing and co-development

<http://techtransfer.cancer.gov/availabletechnologies>

Steven Feldman	Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy	Oncology Immunology	TAB-5074 E-182-2017-0
Raul Sakoda	In vitro Generation of an Autologous Thymic Organoid from Human Pluripotent Stem Cells	Method to produce immune cells	TAB-4206 E-133-2017-0
Yun Ji	Overexpression of Phf19 on T Cells Enhances Therapeutic Effects of T Cell-Based Therapies	Method to epigenetically reprogram CD8+ T cell	TAB-4030 E-107-2017-0
Dimiter Dimitrov	Antibodies and CARs Targeting FLT3 for the Treatment of Acute Myeloid Leukemia and Acute Lymphoid Leukemia	Cancers express FLT3, including AML and ALL	TAB-4105 E-014-2017-0
Liyanage Perera	Chimeric Antigen Receptor (CAR) that Targets Chemokine Receptor CCR4 and its Use in Treating Cancer	Cell therapy platform	TAB-4299 E-258-2016-0
Eric Tran	T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy	Cancers expressing mutant KRAS	TAB-4212 E-175-2016-0
Sanja Stevanovic	T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors	Epithelial tumors	TAB-4438 E-153-2016-0
George Pavlakis	Use of Heterodimeric IL-15 in Adoptive Cell Transfer	Lymphodepletion-associated detrimental side effects	TAB-3971 E-132-2016-0 E-132-2016-1 E-132-2016-2
James Kochenderfer	Chimeric Antigen Receptors (CARs) for Treating Lymphoma and Other Cancers	Cancers expressing CD30 (TNFR superfamily member 8)	TAB-4164 E-001-2016-0
Crystal Mackall	Chimeric Antigen Receptors to CD276 for Treating Cancer	Cancers associated with CD276	TAB-3910 E-243-2015-0

Cell Therapy and T-Cell Receptor Technologies Available for Licensing and co-development

<http://techtransfer.cancer.gov/availabletechnologies>

Sanjivan Gautam	Inhibition of T Cell Differentiation and Senescence by Overexpression of Transcription Factor c-Myb	Improved survival of transferred cells	TAB-4218 E-232-2015-0
Terry Fry	Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs)	Blood cancers	TAB-4268 E-106-2015-0
Kenichi Hanada	Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer	Thyroid cancer	TAB-4198 E-226-2014-0
Christian Hinrichs	T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein	HPV E7 Oncoprotein	TAB-4126 E-176-2014-0
Alena Gros	Improved Personalized Cancer Immunotherapy	Process to select highly tumor-reactive T cells	TAB-4023 E-059-2013-0

Contact:

Michael L. Salgaller, PhD | Supervisory Specialist | Email: Michael.salgaller@nih.gov | Phone: (240) 276-5476
 Joseph M. Conrad III, PhD, JD | Senior Technology Transfer & Marketing Specialist |
 Email: joseph.conrad@nih.gov | Phone: (240) 276-5495